• Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Logo
  • Home
  • About
  • Categories
    • Feature
    • Cardiology trends
    • Cardiology research news
    • Conference coverage
    • Consensus reports & Position papers
    • Videos
  • Contact

Cardiology Update

The latest trends and advancements made in cardiology research.

Ezetimibe added to statin therapy improves cardiovascular outcomes in diabetes mellitus

January 30, 2019

Reading Time: 1 minute

A nonstatin, ezetimibe, inhibits absorption of cholesterol, reduces LDL-C and thereby reduces cardiovascular events after acute coronary syndrome (ACS), when used as an adjunct to statins. In the IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial) Giugliano et al. explored outcomes in 18144 ACS patients randomized to receive ezetimibe/simvastatin (E/S) or placebo/simvastatin. In a pre-specified subgroup of 4933 patients with diabetes mellitus (DM), the authors reported the same beneficial trend of reduced cardiovascular events.  In this subgroup, the primary end point event rate (defined as cardiovascular death, major coronary events and stroke) was decreased by 5.5% absolute; in patients without DM, the absolute difference was 0.7%.  No differences in safety outcomes by treatment were present.  DM patients showed greatest relative reductions in myocardial infarction and ischemic stroke.

Further dichotimization by age showed patients < 75 years of age with DM demonstrated greater benefit than those without. Meanwhile, patients >75 years of age displayed a greater benefit (20% relative reduction in the primary endpoint), regardless of DM.

Giugliano et al. conclude that for patients with an ACS, physicians should consider combining ezetimibe with statins to reduce cardiovascular risk.

In letters from colleagues, Donzelli et al. point out that in patients younger than 75 years of age without DM, endpoints were in fact worse in the E/S group, and that there is little evidence for statin therapy in patients over the age of 75; Koh observes that patients with a low to moderate risk profile demonstrated no added benefit from the addition of ezetimibe to simvastatin, and remarks upon the increased risk of DM with statin use.

Original article:  Circulation. 2018 Apr 10;137(15):1571-1582.
Letters: Circulation. 2018 Oct 23;138(17):1912-1913.
Circulation. 2018 Oct 23;138(17):1914-1915.

Author: Kelly Schoonderwoerd


Check Out Related Articles

  • Statin therapy: clinical benefits and potential risksStatin therapy: clinical benefits and potential risks
  • Top 10 Highlights of TCT 2019Top 10 Highlights of TCT 2019
  • Albiglutide to lower risk of cardiovascular eventsAlbiglutide to lower risk of cardiovascular events

Primary Sidebar

Cardiology News Highlights

  • Facebook
  • Instagram
  • LinkedIn
  • Twitter

Most featured

Statin therapy: clinical benefits and potential risks

Statin therapies prevent both primary and secondary cardiovascular disease.However, long term safety … Continue Reading about Statin therapy: clinical benefits and potential risks

Renin-angiotensin system inhibitors and TAVR

Renin-angiotensin system inhibitors improve TAVR prognosis

Transcatheter aortic valve replacement (TAVR) is a minimally invasive procedure to replace narrowed … Continue Reading about Renin-angiotensin system inhibitors improve TAVR prognosis

AHA 2019 Highlights

AHA 2019: What you need to know

American Heart Association Scientific Sessions, November 16–18, 2019 (Philadelphia, USA) The AHA … Continue Reading about AHA 2019: What you need to know

Browse by topic

Cardiac surgery Electrophysiology General cardiology Heart failure Imaging Interventional cardiology

Footer

Cardiology Update

Providing up-to-date developments in the field of cardiology in a clear and concise manner. All articles are written by professional medical journalists and subsequently reviewed by our editorial board. Cardiology Update provides breaking news, that matter to healthcare professionals in the field of cardiology. Subscribe for free to keep up with cardiology news updated daily.

Recent

  • Renin-angiotensin system inhibitors improve TAVR prognosis
  • AHA 2019: What you need to know
  • Global consensus on CTO-PCI best practices
  • Managing coronary artery disease: MRI vs FFR
  • Prognostic implication of myocardial injury during PCI vs CABG

Search

Browse by topic

Cardiac surgery Electrophysiology General cardiology Heart failure Imaging Interventional cardiology

Terms & Conditions | Privacy | Disclaimer
© Clinicalinx B.V. All rights reserved. Postbus 2278, 1000 CG Amsterdam

We use cookies to provide the services and features offered on our website, and to improve our user experience. Learn more Ok
Privacy & Cookies Policy

Necessary Always Enabled